300 related articles for article (PubMed ID: 8620504)
1. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
[TBL] [Abstract][Full Text] [Related]
2. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons.
Borgnetto ME; Tinelli S; Carminati L; Capranico G
J Mol Biol; 1999 Jan; 285(2):545-54. PubMed ID: 9878428
[TBL] [Abstract][Full Text] [Related]
3. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines.
Binaschi M; Farinosi R; Borgnetto ME; Capranico G
Cancer Res; 2000 Jul; 60(14):3770-6. PubMed ID: 10919649
[TBL] [Abstract][Full Text] [Related]
4. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
5. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
Cornarotti M; Tinelli S; Willmore E; Zunino F; Fisher LM; Austin CA; Capranico G
Mol Pharmacol; 1996 Dec; 50(6):1463-71. PubMed ID: 8967966
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
7. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.
Huff AC; Robinson RG; Evans AC; Selander KN; Wentland MP; Rake JB; Coughlin SA
Anticancer Drug Des; 1995 Apr; 10(3):251-76. PubMed ID: 7748459
[TBL] [Abstract][Full Text] [Related]
8. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Wolverton JS; Danks MK; Granzen B; Beck WT
Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
[TBL] [Abstract][Full Text] [Related]
10. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
12. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
Capranico G; Butelli E; Zunino F
Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
[TBL] [Abstract][Full Text] [Related]
13. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.
Pommier Y; Capranico G; Orr A; Kohn KW
Nucleic Acids Res; 1991 Nov; 19(21):5973-80. PubMed ID: 1658748
[TBL] [Abstract][Full Text] [Related]
14. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
Del Bino G; Darzynkiewicz Z
Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159
[TBL] [Abstract][Full Text] [Related]
15. Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro.
Han YH; Austin MJ; Pommier Y; Povirk LF
J Mol Biol; 1993 Jan; 229(1):52-66. PubMed ID: 8380617
[TBL] [Abstract][Full Text] [Related]
16. Application of a degenerate consensus sequence to quantify recognition sites by vertebrate DNA topoisomerase II.
Spitzner JR; Muller MT
J Mol Recognit; 1989 Sep; 2(2):63-74. PubMed ID: 2561527
[TBL] [Abstract][Full Text] [Related]
17. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
18. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
19. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells.
Tan KB; Mattern MR; Boyce RA; Hertzberg RP; Schein PS
NCI Monogr; 1987; (4):95-8. PubMed ID: 2819739
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites in c-myc proto-oncogene.
Riou JF; Vilarem MJ; Larsen CJ; Multon E; Riou GF
NCI Monogr; 1987; (4):41-7. PubMed ID: 2819730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
